Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12872464 | 0.88 | NCF1 (0.43) | SLC6A4SLC6A3HRH3GNAO1GNAI3 | |
| SCHEMBL26753580 | 0.88 | SLC6A4 (0.39) | SLC6A4SLC6A3HRH3GNAO1KDM1A | |
| SCHEMBL29323908 | 0.88 | GNAO1 (0.38) | SLC6A4SLC6A3HRH3GNAO1GNAI3 | |
| SCHEMBL26743216 | 0.85 | HRH3 (0.45) | SLC6A4SLC6A3HRH3GNAO1KDM1A | |
| SCHEMBL25492962 | 0.85 | NCF1 (0.41) | HRH3GNAO1GNAI3GNAI1KDM1A | |
| SCHEMBL29324792 | 0.84 | CYP2D6 (0.38) | SLC6A4SLC6A3HRH3GNAO1KDM1A | |
| SCHEMBL26741830 | 0.81 | HRH3 (0.48) | HRH3GNAO1GNAI3GNAI1KDM1A | |
| SCHEMBL26747091 | 0.81 | SLC6A4 (0.37) | SLC6A4SLC6A3HRH3 | |
| SCHEMBL29342462 | 0.80 | HRH3 (0.41) | HRH3GNAO1KDM1A | |
| SCHEMBL26744666 | 0.80 | HRH3 (0.39) | SLC6A4SLC6A3HRH3GNAO1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | SLC6A4 3815/4885SLC6A3 2601/4885HRH3 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.